Methods of treating or reducing symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), Bipolar disorder, and related disorders/conditions via combination therapy with vaccine/antibodies and 5ht1/5ht2, SERT and other allosteric modulators.
This patent (application) is a divisional patent filing which claims prior filing date/priority to patent, please reference patent title: Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses. Application Ser. No. 17/667,147—which claims prior filing date to a provisional patent. Please reference the provisional patent title: Psychedelic formulations for medical, recreational, religious, research and other uses. Application No. 63/207,183.
DESCRIPTION
Field OF THE Invention
The invention involves the use of formulations of allosteric modulators of primarily 5ht2a/5ht1a, glutamate or SERT serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, GLP, and other receptors/systems, in combination with phenethylamines, tryptamines, ibogaloids as well as vaccines, antibodies and other compounds; to treat or reduce symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), bipolar disorder, and related disorders/conditions.
Background of the Invention
People across the world are affected by stimulant dependency (addiction) and the serotonin system is believed to be involved in many if not all of these cases.
Pharmaceuticals such as antidepressants, serotonin reuptake inhibitors, selective serotonin reuptake inhibitors, etc. are the current state of art treatments. However, many of these compounds are short acting and come with complicated side effects which make their use and utility limited.
Phenethylamines such as Mescaline, which is the active compound of many cacti, Psilocin/psilocybin containing mushrooms or fungi, have compounds (primarily tryptamines) which cross the blood brain barrier and stimulate the 5-ht receptors. Phenethylamines such as Mescaline normescaline, the 2c series (2C-I/B/E *-NBOH NBOME etc) and MDMA, as well as lysergam ides and ergotamines and beta carbolines have activity on these systems. These compounds provide fast-acting and long-lasting changes to a person's illness.
However, there is variance in the effects these compounds have based on human genetics and related conditions. Allosteric binding occurs at a secondary binding site and not at the orthosteric or main agonist site and thus provides a way for additional compounds to be used in combination to provide ideal binding of receptors for individualized medicine and proper dosing. Allosteric binding affects the affinity and binding rate or activity of the receptor in a variety of ways including, but not limited to changing the shape of the receptor.
SUMMARY OF THE INVENTION
The invention involves the use of formulations of allosteric modulators of primarily 5ht2a/5ht1a, glutamate or SERT serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, GLP, and other receptors/systems, in combination with phenethylamines, tryptamines, ibogaloids as well as vaccines, antibodies and other compounds; to treat or reduce symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), bipolar disorder and related disorders/conditions.
BRIEF DESCRIPTION OF THE DRAWINGS
PAGE 1 of drawings show potential formulations of the compositions in FIG. 1, FIG. 2, FIG. 3 and FIG. 4. FIG. 1 shows a recipe for a mescaline and THCV composition to be taken orally, but may be used in other ways. FIG. 2 shows a recipe for psilocybin, psilocin, CBD, linalool, alpha-pinene and Tetrahydroharmine, composition to be taken orally, but may be used in other ways. FIG. 3 shows a recipe for LSD, CBDV, myrcene and linalool composition to be taken orally, but may be used in other ways. FIG. 4 shows a recipe for psilocybin, psilocin, CBD, linalool, alpha-pinene and Tetrahydroharmine additionally containing 5ht2a positive allosteric modulator oleamide, composition to be taken orally, but may be used in other ways.
PAGES 2-5 of drawings show the results of a human experiment on the use of 4-aco-DIPT, 4-HO-DIPT, 4-aco-DMT, 4-ho-MET, proscaline, 1P-LSD and 5-MEO-DMT alone or with positive 5HT2A allosteric modulators. PAGE 2 shows FIG. 5: 4-aco-DIPT and FIG. 6: 4-HO-DIPT. PAGE 3 shows FIG. 7: 4-aco-DMT and FIG. 8: 4-ho-MET. PAGE 4 shows FIG. 9. Proscaline and FIG. 10: 1P-LSD. PAGE 5 shows FIG. 11 and FIG. 12: 5-MEO-DMT.
PAGES 6-9 of drawings show the results of a human experiment on the use of 4-aco-DIPT, 4-HO-DIPT, 4-aco-DMT, 4-ho-MET, proscaline, 1P-LSD and 5-MEO-DMT alone or with negative 5HT2A allosteric modulators. PAGE 6 shows FIG. 13: 4-aco-DIPT and FIG. 14: 4-HO-DIPT.
PAGE 7 shows FIG. 15: 4-aco-DMT and FIG. 16: 4-ho-MET. PAGE 8 shows FIG. 17. Proscaline and FIG. 18: 1P-LSD. PAGE 9 shows FIG. 19 and FIG. 20: 5-MEO-DMT. LSD alone or with allosteric modulators to modulate fear, anxiety and nausea. The compounds used in addition to the psychedelics were: for Nausea: 5ht3 allosteric modulators: linalool, citral and ginger for nausea; for anxiety and fear: 5ht7 modulator zinc and 5ht1 modulator cannabidiol. FIG. 21: 4-aco-DMT. FIG. 22: Proscaline. FIG. 23: 1P-LSD.
DRAWING SUMMARY
PAGE 1 of drawings show potential formulations of the compositions in FIG. 1, FIG. 2, FIG. 3 and FIG. 4. FIG. 1 shows a recipe for a mescaline and THCV composition to be taken orally, but may be used in other ways. FIG. 2 shows a recipe for psilocybin, psilocin, CBD, linalool, alpha-pinene and Tetrahydroharmine, composition to be taken orally, but may be used in other ways. FIG. 3 shows a recipe for LSD, CBDV, myrcene and linalool composition to be taken orally, but may be used in other ways. FIG. 4 shows a recipe for psilocybin, psilocin, CBD, linalool, alpha-pinene and Tetrahydroharmine additionally containing 5ht2a positive allosteric modulator oleamide, composition to be taken orally, but may be used in other ways.
PAGES 2-5 of drawings show the results of a human experiment on the use of 4-aco-DIPT, 4-HO-DIPT, 4-aco-DMT, 4-ho-MET, proscaline, 1P-LSD and 5-MEO-DMT alone or with positive 5HT2A allosteric modulators. PAGE 2 shows FIG. 5: 4-aco-DIPT and FIG. 6: 4-HO-DIPT. PAGE 3 shows FIG. 7: 4-aco-DMT and FIG. 8: 4-ho-MET. PAGE 4 shows FIG. 9. Proscaline and FIG. 10: 1P-LSD. PAGE 5 shows FIG. 11 and FIG. 12: 5-MEO-DMT.
PAGES 6-9 of drawings show the results of a human experiment on the use of 4-aco-DIPT, 4-HO-DIPT, 4-aco-DMT, 4-ho-MET, proscaline, 1P-LSD and 5-MEO-DMT alone or with negative 5HT2A allosteric modulators. PAGE 6 shows FIG. 13: 4-aco-DIPT and FIG. 14: 4-HO-DIPT. PAGE 7 shows FIG. 15: 4-aco-DMT and FIG. 16: 4-ho-MET. PAGE 8 shows FIG. 17. Proscaline and FIG. 18: 1P-LSD. PAGE 9 shows FIG. 19 and FIG. 20: 5-MEO-DMT.
PAGE 10 shows the results of a human experiment on the use of 4-aco-DMT, proscaline or 1-P-LSD alone or with allosteric modulators to modulate fear, anxiety and nausea. The compounds used in addition to the psychedelics were: for Nausea: 5ht3 allosteric modulators: linalool, citral and ginger for nausea; for anxiety and fear: 5ht7 modulator zinc and 5ht1 modulator cannabidiol. FIG. 21: 4-aco-DMT. FIG. 22: Proscaline. FIG. 23: 1P-LSD.
DETAILED DESCRIPTION OF THE INVENTION
The invention involves the use of formulations of allosteric modulators of primarily 5ht2a/5ht1a, glutamate or SERT serotonin transporter, but also those of: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht7, dopamine, GLP, and other receptors/systems, in combination with phenethylamines, tryptamines, ibogaloids as well as vaccines, antibodies and other compounds; to treat or reduce symptoms of anxiety, depression, attention deficiency (ADD), attention deficient hyperactivity (ADHD), obsessive compulsive (OCD), bipolar disorder and related disorders/conditions.
Allosteric modulation is the manipulation of a receptor at a site other than than normal binding site known as the orthosteric site. This is a less utilized method due to only recent discovery of its mechanisms as well as the need to identify these for each receptor. The use of allosteric modulators allows for precise alterations to the activity at the receptor and thus fine tuning of medical effects. Some embodiments utilize compounds which work as positive or negative allosteric modulators of the 5ht2a receptor or other 5ht systems. Allosteric modulation of 5ht2a also includes allosteric modulation through interaction with other receptor systems such as with hetomers or other such items.
In some embodiments the composition will include purified compounds which are either isolated or just purified. In other embodiments raw extracts or ground/processed biomass may be used. Some embodiments include excipients such as water, cyclodextrin, ethanol or other items off of the Food and Drug Administration authorized and approved excipient list.
Some embodiments will include utilizing nano technology, encapsulation, beta glucan particles, chitosan, yeast extract, surfactants, binders and other compounds to increase efficiency, availability, release lifespan, release speed among other parameters.
Some embodiments are used with vaccines, antibodies, cytokines, proteins, amino acids, DNA, RNA.
Potential compounds can be found below.
Compound List
- LSD, 1P-LSD, 1V-LSD, LSV, ALD-52, AL-LAD, and other LSD analogs, DBT, DET, DiPT, 5-MeO-α-MT, DMT, 2,α-DMT, α,N-DMT, DPT, EiPT, α-ET, ETH-LAD, Harmaline, Harmine, 4-HO-DBT, 4-HO-DET, 4-HO-DiPT, 4-HO-DMT, 5-HO-DMT, 4-HO-DPT, 4-HO-MET, 4-HO-MiPT, 4-HO-MPT, 4-HO-pyr-T, Ibogaine, LSD, MBT, 4,5-MDO-DiPT, 5,6-MDO-DiPT, 4,5-MDO-DMT, 5,6-MDO-DMT, 5,6-MDO-MiPT, 2-Me-DET, 2-Me-DMT, Melatonin, 5-MeO-DET, 5-MeO-DiPT, 5-MeO-DMT, 4-MeO-MiPT, 5-MeO-MiPT, 5,6-MeO-MiPT, 5-MeO-NMT, 5-MeO-pyr-T, 6-MeO-THH, 5-MeO-TMT, 5-MeS-DMT, MiPT, α-MT, NET, NMT, PRO-LAD, pyr-T, Tryptamine, Tetrahydroharmine, α,N,O-TMS, α,N,N-TMT·2,N,N-TMT·5,N,N-TMT-4-Acetoxy-DMT·
- 4-Acetoxy-DET·4-Acetoxy-DIPT·4-HO-5-MeO-DMT·α-ET·α-MT·Baeocystin·Bufotenin·DBT·DET·DIPT·DMT·EiPT·PiPT·Ethocin·Ethocybin·Iprocin·4-HO-MET·4-HO-MiPT·MET·MIPT·5-Me-MIPT·5-MeO-α-ET·5-MeO-α-MT·5-MeO-DALT·5-MeO-DET·5-MeO-DIPT·5-MeO-DMT·5-MeO-DPT·5MeO-DPT·5-MeO-MET·5-MeO-MIPT·5-MeO-αN,N-TMT·5-MeO-2,N,N-TMT·Miprocin·Norbaeocystin·Psilocin·Psilocybin,4-HO-MALT, 4-Acetoxy-DET·4-Acetoxy-DIPT·4-Acetoxy-DMT·4-HO-DIPT·5-Bromo-DMT·5-Fluora-α-MT·5-MeO-α-ET·5-MeO-α-MT·5-MeO-DALT·5-MeO-DET·5-MeO-DIPT·5MeO-DMT·5-MeO-DPT·5-MeO-MIPT·α-ET·αMT·Baeocystin·Bufotenin·DET·DiPT·DMT·DPT·Ethocybin·EiPT·Ethocin·Ibogaine·Iprocin·MET·MiPT·Miprocin·Melatonin·NMT Norbaeocystin·Normelatonin·PiPT·Psilocin·Psilocybin·Rizatriptan·Serotonin·Sumatriptan·Trypta mine·
- Psilocybin (4-PO-HO-DMT), psilocin (4-HO-DMT), norpsilocin (ω-N-Methyl-4-hydroxytryptamine), baeocystin (4-PO-DMT), norbaeocystin (4-MeO-MIPT), Aeruginascin (N,N,N-trimethyl-4-phosphoryloxytryptamine), bufotenin (5-HO-DMT), 5-MEO-DMT, N,N-Dimethyltryptamine (N,N-DMT), 4-ACO-DMT, N-acetyl-4-hydroxytryptamine, 4-acetoxy-N-ethyl-N-methyltryptammonium (4-AcO-MET), 4-acetoxy-N,N-diallyltryptammonium (4-AcO-DALT) acid, 4-acetoxy-N-allyl-N-methyltryptammonium (4-AcO-MALT), N,N-dimethyl-N-n-propyltryptammonium (DMPT), N-allyl-N,N-dimethyltryptammonium (DMALT), 4-HO-TMT (4-hydroxy-N,N,N-trimethyltryptamine), N-methyltryptamine, 4-HO-NMT, 5-HO-NMT, 5-PO-HO-DMT, 4-PO-HO-NMT, 5-PO-HO-NMT, 4-HO-NMT, 4-HO-DMT, N-Methyl-4-phosphoryloxytryptamine, N,N-diethyl-tryptamine, 4-hydroxy-N,N-diethyltryptamine, 4-phosphoryloxy-N,N-diethyltryptamine, 5-HO-DET, 5-PO-DET, 4-PO-HO-DET, 5-PO-HO-DET, 5-PO-HO-DMT, 5-ACO-DMT, 4-ACO-NMT, 4-ACO-DET, 5-ACO-DET, 5-ACO-NMT, 4-hydroxy-6-methyl-L-tryptophan, 6-methyl psilocybin, 6-methyl psilocin, 6-methyl norpsilocin, 6-methyl baeocystin, 6-methyl norbaeocystin, 6-methyl Aeruginascin, 6-methyl bufotenin, 6-methylindole, 3-methylindole, 3-methyl baeocystin, 3-methyl norbaeocystin, 3-methyl Aeruginascin, 3-methyl bufotenin, 7-methylindole, 7-methyl baeocystin, 7-methyl norbaeocystin, 7-methyl Aeruginascin, 7-methyl bufotenin, 4-hydroxy-3-methyl-L-tryptophan, 4-hydroxy-7-methyl-L-tryptophan, 5-ht, gaba (gamma-Aminobutyric acid), serotonin, dopamine, epinephrine, oxytocin, tryptamine. 5-Bromo-DMT, 5,6-Dibromo-DMT, 4-aco-mpt, 4-aco-mipt, 4-aco-ept, 4-aco-dipt, 4-aco-dpt.
Iboga alkaloids such as, but not limited to: Coronaridine, Ibogamine, Voacangine, Ibogaine, conopharyngine, ibogaline, stemmadenine, noribogaine.
Cannabinoids including, but not limited to: endocannabinoids, phytocannabinoids, compounds which are ligands at CB1 or CB2 receptors such as, but not limited to: 2-AG, anandamide, CBD cannabidiol, THC (Tetrahydrocannabinol), Tetrahydrocannabivarin THCV, CBDV Cannabidivarin, tetrahydrocannabiphorol THCP, cannabidiphorol CBDP, hexyl CBD, THC acetates, CBD acetates, Cannabigerovarin CBGV, CBG cannabigerol, CBG acetates, heli-CBG, (CBC) cannabichromene, Cannabichromevarin CBCV, cannabinol CBN, beta caryophyllene, also butyl, hexyl, hepyl, octyl, deca, versions. Cannabinoids include all isomers including delta-8, delta-9, delta-10 and beyond such as for THC, but also including other cannabinoids.
Terpenes and terpenoids, such as, but not limited to: limonene, alpha-pinene, myrcene, linalool, terpinolene and all isomers of such compounds.
Phenethylamines including, but not limited to: mescaline, normescaline, 2c-i,2c-b, 2c-e. Includes all: phenethylamines in 2(X) series such as 2-CI including all NBOME, NBOH, and other analogs.
Beta carbolines and maoi inhibitors including, but not limited to: harmaline, tetraharmaline, norharmane, perlolyrine, tetrahydroharmine, harmane, harmine, harmol.
|
1
AEM
alpha-Ethyl-3,4,5-trimethoxy-PEA
|
2
AL
4-Allyloxy-3,5-dimethoxy-PEA
|
3
ALEPH
4-Methylthio-2,5-dimethoxy-A
|
4
ALEPH-2
4-Ethylthio-2,5-dimethoxy-A
|
5
ALEPH-4
4-Isopropylthio-2,5-dimethoxy-A
|
6
ALEPH-6
4-Phenylthio-2,5-dimethoxy-A
|
7
ALEPH-7
4-Propylthio-2,5-dimethoxy-A
|
8
ARIADNE
2,5-Dimethoxy-alpha-ethyl-4-methyl-PEA
|
9
ASB
3,4-Diethoxy-5-methoxy-PEA
|
10
B
4-Butoxy-3,5-dimethoxy-PEA
|
11
BEATRICE
2,5-Dimethoxy-4,N-dimethyl-A
|
12
BIS-TOM
2,5-Bismethylthio-4-methyl-A
|
13
BOB
4-Bromo-2,5, beta-trimethoxy-PEA
|
14
BOD
2,5,beta-Trimethoxy-4-methyl-PEA
|
15
BOH
beta-Methoxy-3,4-methylenedioxy-PEA
|
16
BOHD
2,5-Dimethoxy-beta-hydroxy-4-methyl-PEA
|
17
BOM
3,4,5, beta-Tetram ethoxy-P E A
|
18
4-Br-3,5-DMA
4-Bromo-3,5-dimethoxy-A
|
19
2-Br-4,5-MDA
2-Bromo-4,5-methylenedioxy-A
|
20
2C-B
4-Bromo-2,5-dimethoxy-PEA
|
21
3C-BZ
4-Benzyloxy-3,5-dimethoxy-A
|
22
2C-C
4-Chloro-2,5-dimethoxy-PEA
|
23
2C-D
4-Methyl-2,5-dimethoxy-PEA
|
24
2C-E
4-Ethyl-2,5-dimethoxy-PEA
|
25
3C-E
4-Ethoxy-3,5-dimethoxy-A
|
26
2C-F
4-Fluoro-2,5-dimethoxy-PEA
|
27
2C-G
3,4-Dimethyl-2,5-dimethoxy-PEA
|
28
2C-G-3
3,4-Trimethylene-2,5-dimethoxy-PEA
|
29
2C-G-4
3,4-Tetramethylene-2,5-dimethoxy-PEA
|
30
2C-G-5
3,4-Norbornyl-2,5-dimethoxy-PEA
|
31
2C-G-N
1,4-Dimethoxynaphthyl-2-ethylamine
|
32
2C-H
2,5-Dimethoxy-PEA
|
33
2C-I
4-lodo-2,5-dimethoxy-PEA
|
34
2C-N
4-Nitro-2,5-dimethoxy-PEA
|
35
2C-O-4
4-Isopropoxy-2,5-dimethoxy-PEA
|
36
2C-P
4-Propyl-2,5-dimethoxy-PEA
|
37
CPM
4-Cyclopropylmethoxy-3,5-dimethoxy-PEA
|
38
2C-SE
4-Methylseleno-2,5-dimethoxy-PEA
|
39
2C-T
4-Methylthio-2,5-dimethoxy-PEA
|
40
2C-T-2
4-Ethylthio-2,5-dimethoxy-PEA
|
41
2C-T-4
4-Isopropylthio-2,5-dimethoxy-PEA
|
42
psi-2C-T-4
4-Isopropylthio-2,6-dimethoxy-PEA
|
43
2C-T-7
4-Propylthio-2,5-dimethoxy-PEA
|
44
2C-T-8
4-Cyclopropylmethylthio-2,5-dimethoxy-PEA
|
45
2C-T-9
4-(t)-Butylthio-2,5-dimethoxy-PEA
|
46
2C-T-13
4-(2-Methoxyethylthio)-2,5-dimethoxy-PEA
|
47
2C-T-15
4-Cyclopropylthio-2,5-dimethoxy-PEA
|
48
2C-T-17
4-(s)-Butylthio-2,5-dimethoxy-PEA
|
49
2C-T-21
4-(2-Fluoroethylthio)-2,5-dimethoxy-PEA
|
50
4-D
4-Trideuteromethyl-3,5-dimethoxy-PEA
|
51
beta-D
beta,beta-Dideutero-3,4,5-trimethoxy-PEA
|
52
DESOXY
4-Methyl-3,5-Dimethoxy-PEA
|
53
2,4-DMA
2,4-Dimethoxy-A
|
54
2,5-DMA
2,5-Dimethoxy-A
|
55
3,4-DMA
3,4-Dimethoxy-A
|
56
DMCPA
2-(2,5-Dimethoxy-4-methylphenyl)-
|
cyclopropylamine
|
57
DME
3,4-Dimethoxy-beta-hydroxy-PEA
|
58
DMMDA
2,5-Dimethoxy-3,4-methylenedioxy-A
|
59
DMMDA-2
2,3-Dimethoxy-4,5-methylenedioxy-A
|
60
DMPEA
3,4-Dimethoxy-PEA
|
61
DOAM
4-Amyl-2,5-dimethoxy-A
|
62
DOB
4-Bromo-2,5-dimethoxy-A
|
63
DOBU
4-Butyl-2,5-dimethoxy-A
|
64
DOC
4-Chloro-2,5-dimethoxy-A
|
65
DOEF
4-(2-Fluoroethyl)-2,5-dimethoxy-A
|
66
DOET
4-Ethyl-2,5-dimethoxy-A
|
67
DOI
4-lodo-2,5-dimethoxy-A
|
68
DOM (STP)
4-Methyl -2,5-dimethoxy-A
|
69
psi-DOM
4-Methyl -2,6-dimethoxy-A
|
70
DON
4-Nitro-2,5-dimethoxy-A
|
71
DOPR
4-Propyl-2,5-dimethoxy-A
|
72
E
4-Ethoxy-3,5-dimethoxy-PEA
|
73
EEE
2,4,5-Triethoxy-A
|
74
EEM
2,4-Diethoxy-5-methoxy-A
|
75
EME
2,5-Diethoxy-4-methoxy-A
|
76
EMM
2-Ethoxy-4,5-dimethoxy-A
|
77
ETHYL-J
N, alpha-diethyl-3,4-methylenedioxy-PEA
|
78
ETHYL-K
N-Ethyl-alpha-propyl-3,4-methylenedioxy-PEA
|
79
F-2
Benzofuran-2-methyl-5-methoxy-
|
6-(2-aminopropane )
|
80
F-22
Benzofuran-2,2-dimethyl-5-
|
methoxy-6-(2-aminoprop ane)
|
81
FLEA
N-Hydroxy-N-methyl-3,4-methylenedioxy-A
|
82
G-3
3,4-Trimethylene-2,5-dimethoxy-A
|
83
G-4
3,4-Tetramethylene-2,5-dimethoxy-A
|
84
G-5
3,4-Norbornyl-2,5-dimethoxy-A
|
85
GANESHA
3,4-Dimethyl-2,5-dimethoxy-A
|
86
G-N
1,4-Dimethoxynaphthyl-2-isopropylamine
|
87
HOT-2
2,5-Dimethoxy-N-hydroxy-4-ethylthio-PEA
|
88
HOT-7
2,5-Dimethoxy-N-hydroxy-4-(n)-propylthio-PEA
|
89
HOT-17
2,5-Dimethoxy-N-hydroxy-4-(s)-butylthio-PEA
|
90
IDNNA
2,5-Dimethoxy-N,N-dimethyl-4-iodo-A
|
91
IM
2,3,4-Trimethoxy-PEA
|
92
IP
3,5-Dimethoxy-4-isopropoxy-PEA
|
93
IRIS
5-Ethoxy-2-methoxy-4-methyl-A
|
94
J
alpha-Ethyl-3,4-methylenedioxy-PEA
|
95
LOPHOPHINE
3-Methoxy-4,5-methylenedioxy-PEA
|
96
M
3,4,5-Trimethoxy-PEA
|
97
4-MA
4-Methoxy-A
|
98
MADAM-6
2,N-Dimethyl-4,5-methylenedioxy-A
|
99
MAL
3,5-Dimethoxy-4-methallyloxy-PEA
|
100
MDA
3,4-Methylenedioxy-A
|
101
MDAL
N-Allyl-3,4-methylenedioxy-A
|
102
MDBU
N-Butyl-3,4-methylenedioxy-A
|
103
MDBZ
N-Benzyl-3,4-methylenedioxy-A
|
104
MDCPM
N-Cyclopropylmethyl-3,4-methylenedioxy-A
|
105
MDDM
N,N-Dimethyl-3,4-methylenedioxy-A
|
106
MDE
N-Ethyl-3,4-methylenedioxy-A
|
107
MDHOET
N-(2-Hydroxyethyl)-3,4-methylenedioxy-A
|
108
MDIP
N-Isopropyl-3,4-methylenedioxy-A
|
109
MDMA
N-Methyl-3,4-methylenedioxy-A
|
110
MDMC
N-Methyl-3,4-ethylenedioxy-A
|
111
MDMEO
N-Methoxy-3,4-methylenedioxy-A
|
112
MDMEOET
N-(2-Methoxyethyl)-3,4-methylenedioxy-A
|
113
MDMP
alpha,alpha, N-Trimethyl-3,4-
|
methylenedioxy-PEA
|
114
MDOH
N-Hydroxy-3,4-methylenedioxy-A
|
115
MDPEA
3,4-Methylenedioxy-PEA
|
116
MDPH
alpha,alpha-Dimethyl-3,4-methylenedioxy-PEA
|
117
MDPL
N-Propargyl-3,4-methylenedioxy-A
|
118
MDPR
N-Propyl-3,4-methylenedioxy-A
|
119
ME
3,4-Dimethoxy-5-ethoxy-PEA
|
120
MEDA
3-methoxy-4,5-Ethylenedioxy-A
|
[Erowid corrected]
|
121
MEE
2-Methoxy-4,5-diethoxy-A
|
122
MEM
2,5-Dimethoxy-4-ethoxy-A
|
123
MEPEA
3-Methoxy-4-ethoxy-PEA
|
124
META-DOB
5-Bromo-2,4-dimethoxy-A
|
125
META-DOT
5-Methylthio-2,4-dimethoxy-A
|
126
METHYL-DMA
N-Methyl-2,5-dimethoxy-A
|
127
METHYL-DOB
4-Bromo-2,5-dimethoxy-N-methyl-A
|
128
METHYL-J
N-Methyl-alpha-ethyl-3,4-methylenedioxy-PEA
|
129
METHYL-K
N-Methyl-alpha-propyl-3,4-methylenedioxy-PEA
|
130
METHYL-MA
N-Methyl-4-methoxy-A
|
131
METHYL-
N-Methyl-2-methoxy-4,5-methylenedioxy-A
|
MMDA-2
|
132
MMDA
3-Methoxy-4,5-methylenedioxy-A
|
133
MMDA-2
2-Methoxy-4,5-methylenedioxy-A
|
134
MMDA-3a
2-Methoxy-3,4-methylenedioxy-A
|
135
MMDA-3b
4-Methoxy-2,3-methylenedioxy-A
|
136
MME
2,4-Dimethoxy-5-ethoxy-A
|
137
MP
3,4-Dimethoxy-5-propoxy-PEA
|
138
MPM
2,5-Dimethoxy-4-propoxy-A
|
139
ORTHO-DOT
2-Methylthio-4,5-dimethoxy-A
|
140
P
3,5-Dimethoxy-4-propoxy-PEA
|
141
PE
3,5-Dimethoxy-4-phenethyloxy-PEA
|
142
PEA
PEA
|
143
PROPYNYL
4-Propynyloxy-3,5-dimethoxy-PEA
|
144
SB
3,5-Diethoxy-4-methoxy-PEA
|
145
TA
2,3,4,5-Tetramethoxy-A
|
146
3-TASB
4-Ethoxy-3-ethylthio-5-methoxy-PEA
|
172
5-TOM
2-Methoxy-4-methyl-5-methylthio-A
|
173
TOMSO
2-Methoxy-4-methyl-5-methylsulfinyl-A
|
174
TP
4-Propylthio-3,5-dimethoxy-PEA
|
175
TRIS
3,4,5-Triethoxy-PEA
|
176
3-TSB
3-Ethoxy-5-ethylthio-4-methoxy-PEA
|
177
4-TSB
3,5-Diethoxy-4-methylthio-PEA
|
178
3-T-TRIS
4,5-Diethoxy-3-ethylthio-PEA
|
179
4-T-TRIS
3,5-Diethoxy-4-ethylthio-PEA
|
|
Additionally includes all: (4-acetoxy) (4-hydroxy)(dimethyl) (diethyl) (N-methyl-N-ethyl) (N-methyl)(N-methyl-N-isopropyl)(N,N-diisopropyl) variations of compounds in compound list.
Additionally includes all: functional group variants, fumerates, fumerics, idoines, hydrofumarates, deneutered or not, salts, acids, isomers, analogs, precursors, further metabolites of biosynthetic or synthetic pathways.
Also: Zinc, Magnesium, Sulfate, Carvelidol.